Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions

References

• Cattaneo D, Baldelli S, Cozzi V, et al. Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of people living with HIV: a narrative review. Ther Drug Monit. 2020;42(1):64–74. doi: 10.1097/FTD.0000000000000684
   PubMed Web of Science ®Google Scholar
• Schou MD, Søgaard OS, Rasmussen TA. Clinical trials aimed at HIV cure or remission: new pathways and lessons learned. Expert Rev Anti Infect Ther. 2023;21(11):1227–1243. doi: 10.1080/14787210.2023.2273919
   PubMedGoogle Scholar
• Collini P, Mawson RL. A new era of HIV care for age-associated multimorbidity. Curr Opin Infect Dis. 2023 Feb 1;36(1):9–14. doi: 10.1097/QCO.0000000000000890
   PubMed Web of Science ®Google Scholar
• Bares SH, Scarsi KK. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Curr Opin HIV AIDS. 2022;17(1):22–31. doi: 10.1097/COH.0000000000000708
   PubMed Web of Science ®Google Scholar
• Cunha RF, Simões S, Carvalheiro M, et al. Novel antiretroviral therapeutic strategies for HIV. Molecules. 2021;26(17):5305. doi: 10.3390/molecules26175305
   PubMed Web of Science ®Google Scholar
• Clemente T, Galli L, Poli A, et al. Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting. Int J Antimicrob Agents. 2023 Aug;62(2):106897. doi: 10.1016/j.ijantimicag.2023.106897
   PubMed Web of Science ®Google Scholar
• Peng AT, Huang SH, Lee HY, et al. Polypharmacy and potential drug-drug interactions among people living with HIV in the era of integrase strand-transferase inhibitor-based antiretroviral therapy. Int J Antimicrob Agents. 2023 Dec 22;63(2):107067. doi: 10.1016/j.ijantimicag.2023.107067
   PubMed Web of Science ®Google Scholar
• Hodge D, Hodel EM, Hughes E, et al. Prevalence of potentially clinically significant drug-drug interactions with antiretrovirals against hiv over three decades: a systematic review of the literature. J Acquir Immune Defic Syndr. 2023;92(2):97–105. doi: 10.1097/QAI.0000000000003122
   PubMed Web of Science ®Google Scholar
• Sevenler D, Niu X, Dossantos S, et al. Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate. J Antimicrob Chemother. 2022;77(4):996–999. doi: 10.1093/jac/dkab487
   PubMed Web of Science ®Google Scholar
• Phillips T, Gomba Y, Myer L. Comparing a point-of-care urine tenofovir lateral flow assay to self-reported adherence and their associations with viral load suppression among adults on antiretroviral therapy. Trop Med Int Health. 2024;29(2):96–103. doi: 10.1111/tmi.13953
   PubMed Web of Science ®Google Scholar
• Nematadzira TG, Murnane PM, Odiase OJ, et al. Antiretroviral therapy adherence during and postbreastfeeding cessation measured by tenofovir levels in hair. J Acquir Immune Defic Syndr. 2022;91(3):237–241. doi: 10.1097/QAI.0000000000003076
   PubMed Web of Science ®Google Scholar
• Chawana TD, Nhachi CFB, Nathoo K, et al. Brief report: ritonavir concentrations in hair predict virologic outcomes in HIV-Infected adolescents WithVirologic failure on atazanavir-based or ritonavir-based second-line treatment. J Acquir Immune Defic Syndr. 2021;88(2):181–185. doi: 10.1097/QAI.0000000000002742
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li X, Qiao S, et al. Association of hair concentrations of antiretrovirals with virologic outcomes among people living with HIV in Guangxi, China. Patient Prefer Adherence. 2021;15:853–861. doi: 10.2147/PPA.S277965
   PubMed Web of Science ®Google Scholar
• Okochi H, Louie A, Phung N, et al. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART. Drug Test Anal. 2021;13(7):1354–1370. doi: 10.1002/dta.3033
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Baldelli S, Castoldi S, et al. Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint. AIDS. [2014 Oct 23];28(16):2477–2480. doi: 10.1097/QAD.0000000000000440
   PubMed Web of Science ®Google Scholar
• Venuto CS, Lim J, Messing S, et al. Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS clinical trials group protocol A5224s. Antivir Ther. 2018;23(4):345–351. doi: 10.3851/IMP3209
   PubMed Web of Science ®Google Scholar
• Ximenez JP, Elias ABR, Nardotto GHB, et al. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort. Br J Clin Pharmacol. 2022;88(10):4585–4594. doi: 10.1111/bcp.15387
   PubMed Web of Science ®Google Scholar
• Calcagno A, Dal Conte I, Cattaneo D, et al. Low tenofovir plasma exposure in HIV oral pre-exposure prophylaxis recipients with gastrointestinal disorders. Antimicrob Agents Chemother. 2021;65(1):e01902–20. doi: 10.1128/AAC.01902-20
   PubMed Web of Science ®Google Scholar
• Barcelo C, Aouri M, Courlet P, et al. Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. J Antimicrob Chemother. 2019;74(9):2690–2697. doi: 10.1093/jac/dkz217
   PubMed Web of Science ®Google Scholar
• Cottura N, Kinvig H, Grañana-Castillo S, et al. Drug-drug interactions in people living with hiv at risk of hepatic and renal impairment: current status and future perspectives. J Clin Pharmacol. 2022;62(7):835–846. doi: 10.1002/jcph.2025
   PubMed Web of Science ®Google Scholar
• Talathi R, Anekwe CV, Toribio M. Epidemiology of obesity among people with HIV. Curr Opin HIV AIDS. 2024 Jan 1;19(1):1–5. doi: 10.1097/COH.0000000000000830
   PubMed Web of Science ®Google Scholar
• Guehi C, Badjé A, Gabillard D, et al. High prevalence of being overweight and obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 temprano trial. AIDS Res Therapy. 2016;13(1):12. doi: 10.1186/s12981-016-0094-y
   PubMedGoogle Scholar
• Capeau J, Lagathu C, Béréziat V. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV. Curr Opin HIV AIDS. 2024;19(1):14–20. doi: 10.1097/COH.0000000000000833
   PubMed Web of Science ®Google Scholar
• Madelain V, Le MP, Champenois K, et al. Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study. J Antimicrob Chemother. 2017;72(4):1137–1146. doi: 10.1093/jac/dkw527
   PubMed Web of Science ®Google Scholar
• Zino L, van Bussel LPM, Greupink R, et al. The impact of obesity on doravirine exposure in people with HIV. AIDS. 2024;38(2):267–269. doi: 10.1097/QAD.0000000000003765
   PubMed Web of Science ®Google Scholar
• Berton M, Bettonte S, Stader F, et al. Antiretroviral drug exposure and response in obese and morbidly obese people with human immunodeficiency virus (HIV): a study combining modelling and Swiss HIV Cohort Data. Clin Infect Dis. 2024;78(1):98–110. doi: 10.1093/cid/ciad495
   PubMed Web of Science ®Google Scholar
• Berton M, Bettonte S, Stader F, et al. Impact of obesity on the drug-drug interaction between dolutegravir and rifampicin or any other strong inducers. Open Forum Infect Dis. 2023;10(7):ofad361. doi: 10.1093/ofid/ofad361
   PubMed Web of Science ®Google Scholar
• Cutrell AG, Schapiro JM, Perno CF, et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS. 2021;35(9):1333–1342. doi: 10.1097/QAD.0000000000002883
   PubMed Web of Science ®Google Scholar
• Elliot E, Polli JW, Patel P, et al. Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials. J Infect Dis. 2023;[Epub ahead of print]. doi: 10.1093/infdis/jiad580
   Google Scholar
• Zino L, Kingma JS, Marzolini C, et al. Implications of bariatric surgery on the pharmacokinetics of antiretrovirals in people living with HIV. Clin Pharmacokinet. 2022;61(5):619–635. doi: 10.1007/s40262-022-01120-7
   PubMed Web of Science ®Google Scholar
• Zino L, Wit F, Rokx C, et al. Outcomes of bariatric surgery in people with human immunodeficiency virus: a retrospective analysis from the ATHENA cohort. Clin Infect Dis. 2023;77(11):1561–1568. doi: 10.1093/cid/ciad404
   PubMed Web of Science ®Google Scholar
• Konstantinidou SK, Argyrakopoulou G, Dalamaga M, et al. The effects of bariatric surgery on pharmacokinetics of drugs: a review of current evidence. Curr Nutr Rep. 2023;12(4):695–708. doi: 10.1007/s13668-023-00498-5
   PubMedGoogle Scholar
• Gervasoni C, Cattaneo D, Resnati C, et al. The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. Eur J Clin Pharmacol. 2017;73(6):789–790. doi: 10.1007/s00228-017-2231-5
   PubMed Web of Science ®Google Scholar
• Muzard L, Alvarez JC, Gbedo C, et al. Tenofovir pharmacokinetic after sleeve-gastrectomy in four severely obese patients living with HIV. Obes Res Clin Pract. 2017;11(1):108–113. doi: 10.1016/j.orcp.2016.06.004
   PubMed Web of Science ®Google Scholar
• Pourcher G, Peytavin G, Schneider L, et al. Bariatric surgery in HIV patients: experience of an obesity reference center in France. Surg Obes Relat Dis. 2017;13(12):1990–1996. doi: 10.1016/j.soard.2017.09.514
   PubMed Web of Science ®Google Scholar
• Amouyal C, Buyse M, Lucas-Martini L, et al. Sleeve gastrectomy in morbidly obese HIV patients: focus on antiretroviral treatment absorption after surgery. Obes Surg. 2018;28(9):2886–2893. doi: 10.1007/s11695-018-3308-7
   PubMed Web of Science ®Google Scholar
• Israel S, Elinav H, Elazary R, et al. Case report of increased exposure to antiretrovirals following sleeve gastrectomy. Antimicrob Agents Chemother. 2020;64(4):e02453–19. doi: 10.1128/AAC.02453-19
   PubMed Web of Science ®Google Scholar
• Huesgen E, DeSear KE, Egelund EF, et al. A HAART-Breaking review of alternative antiretroviral administration: practical considerations with crushing and enteral tube scenarios. Pharmacotherapy. 2016 Nov;36(11):1145–1165. doi: 10.1002/phar.1835
   PubMed Web of Science ®Google Scholar
• Roskam-Kwint M, Bollen P, Colbers A, et al. Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure. J Antimicrob Chemother. 2018;73(9):2430–2434. doi: 10.1093/jac/dky191
   PubMed Web of Science ®Google Scholar
• Hocqueloux L, Lefeuvre S, Bois J, et al. Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study. J Antimicrob Chemother. 2022;78(1):161–168. doi: 10.1093/jac/dkac369
   PubMed Web of Science ®Google Scholar
• Chrdle A, Jerhotová Z, Vacík M, et al. Crushed dolutegravir/abacavir/lamivudine given via nasogastric tube in gastric outlet obstruction caused by cancer resulted in rapid viral load suppression. Int J STD AIDS. 2019 Jan;30(1):94–98. doi: 10.1177/0956462418797847
   PubMed Web of Science ®Google Scholar
• Ragonnet G, Laroche H, Néant N, et al. Enteral administration of crushed rilpivirine in a patient with HIV: a case report. Br J Clin Pharmacol. 2024;90(3):895–899. doi: 10.1111/bcp.15994
   PubMed Web of Science ®Google Scholar
• Abraham AG, Althoff KN, Jing Y, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015;60(6):941–949. doi: 10.1093/cid/ciu919
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Gervasoni C. Novel antiretroviral drugs in patients with renal impairment: clinical and pharmacokinetic considerations. Eur J Drug Metab Pharmacokinet. 2017;42(4):559–572. doi: 10.1007/s13318-016-0394-6
   PubMed Web of Science ®Google Scholar
• Dandachi D, Fabricius M, Saad B, et al. Antiretrovirals for people with HIV on dialysis. AIDS Patient Care STDS. 2022;36(3):86–96. doi: 10.1089/apc.2021.0173
   PubMed Web of Science ®Google Scholar
• EACS Guidelines Version 12.0. 2023 Oct [cited 2024 Feb 7]. Available from: https://www.eacsociety.org/media/guidelines-12.0.pdf
   Google Scholar
• Magee M, Slater J, Mannino F, et al. Effect of renal and hepatic impairment on the pharmacokinetics of Temsavir, the active moiety of Fostemsavir. J Clin Pharmacol. 2021;61(7):939–953. doi: 10.1002/jcph.1810
   PubMed Web of Science ®Google Scholar
• Moltó J, Graterol F, Curran A, et al. Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease. J Antimicrob Chemother. 2022;77(7):1989–1991. doi: 10.1093/jac/dkac126
   PubMed Web of Science ®Google Scholar
• Yee KL, Ouerdani A, Claussen A, et al. Population pharmacokinetics of doravirine and exposure-response analysis in individuals with HIV-1. Antimicrob Agents Chemother. 2019;63(4):e02502–18. doi: 10.1128/AAC.02502-18
   PubMed Web of Science ®Google Scholar
• Kushida H, Watanabe D, Yagura H, et al. Evaluation of plasma doravirine concentrations in patients with HIV-1 undergoing hemodialysis. J Infect Chemother. 2023;29(5):558–561. doi: 10.1016/j.jiac.2023.02.003
   PubMedGoogle Scholar
• Yu X, Zhao L, Yuan Z, et al. Pharmacokinetic drug-drug interactions involving antiretroviral agents: an update. Curr Drug Metab. 2023;24(7):493–524. doi: 10.2174/1389200224666230418093139
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Oreni L, Meraviglia P, et al. Polypharmacy and aging in people living with hiv: 6 years of experience in a multidisciplinary outpatient clinic. Drugs Aging. 2023;40(7):665–674. doi: 10.1007/s40266-023-01037-1
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Fusi M, Micheli V, et al. Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens. AIDS. 2021;35(15):2551–2553. doi: 10.1097/QAD.0000000000003045
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Bonora S, Meraviglia P, et al. Tenofovir plasma trough concentrations in people living with HIV treated with tenofovir disoproxyl fumarate: antiretroviral class or individual drug effect? Ther Drug Monit. 2023;45(2):282–284. doi: 10.1097/FTD.0000000000001072
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Pagano S, Colombo ML, et al. Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations: a focus on novel dual regimens. AIDS. 2024;38(6):847–851. doi: 10.1097/QAD.0000000000003843
   PubMed Web of Science ®Google Scholar
• Sousa M, Pozniak A, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother. 2008;62(5):872–878. doi: 10.1093/jac/dkn330
   PubMed Web of Science ®Google Scholar
• Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21–27. doi: 10.1097/QAI.0b013e318276cda9
   PubMed Web of Science ®Google Scholar
• Wang X, Cerrone M, Ferretti F, et al. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. Int J Antimicrob Agents. 2019;54(2):202–206. doi: 10.1016/j.ijantimicag.2019.04.009
   PubMed Web of Science ®Google Scholar
• Barcelo C, Aouri M, Courlet P, et al. Population pharmacokinetics of dolutegravir: influence of drug–drug interactions in a real-life setting. J Antimicrob Chemother. 2019;74(9):2690–2697. doi: 10.1093/jac/dkz217
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Riva A, Columpsi P, et al. Dosing of Dolutegravir in TB/HIV coinfected patients on rifampicin: twice is (always) better than Once. J Acquir Immune Defic Syndr. 2020;84(3):e17–e20. doi: 10.1097/QAI.0000000000002352
   PubMedGoogle Scholar
• Modongo C, Wang Q, Dima M, et al. Clinical and virological outcomes of TB/HIV coinfected patients treated with Dolutegravir-based HIV antiretroviral regimens: programmatic experience from Botswana. J Acquir Immune Defic Syndr. 2019;82(2):111–115. doi: 10.1097/QAI.0000000000002126
   PubMed Web of Science ®Google Scholar
• Griesel R, Zhao Y, Simmons B, et al. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial. Lancet HIV. 2023;10(7):e433–e441. doi: 10.1016/S2352-3018(23)00081-4
   PubMed Web of Science ®Google Scholar
• Kawuma AN, Wasmann RE, Dooley KE, et al. Population pharmacokinetic model and alternative dosing regimens for dolutegravir coadministered with rifampicin. Antimicrob Agents Chemother. 2022;66(6):e0021522. doi: 10.1128/aac.00215-22
   PubMed Web of Science ®Google Scholar
• Leyes P, Martínez E, Forga Mde T. Use of diet, nutritional supplements and exercise in HIV-infected patients receiving combination antiretroviral therapies: a systematic review. Antivir Ther. 2008;13(2):149–160. doi: 10.1177/135965350801300208
   PubMed Web of Science ®Google Scholar
• Tinggaard M, David KP, Gerstoft J, et al. Potential drug–drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: a clinical survey. HIV Med. 2023;24(1):46–54. doi: 10.1111/hiv.13321
   PubMed Web of Science ®Google Scholar
• Brooks KM, George JM, Kumar P. Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products. Expert Rev Clin Pharmacol. 2017;10(1):59–79. doi: 10.1080/17512433.2017.1246180
   PubMed Web of Science ®Google Scholar
• Stolbach A, Paziana K, Heverling H, et al. A review of the toxicity of HIV Medications II: interactions with drugs and complementary and alternative medicine products. J Med Toxicol. 2015;11(3):326–341. doi: 10.1007/s13181-015-0465-0
   PubMed Web of Science ®Google Scholar
• Orkin C, Schapiro JM, Perno CF, et al. Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure. Clin Infect Dis. 2023;77(10):1423–1431. doi: 10.1093/cid/ciad370
   PubMed Web of Science ®Google Scholar
• Thoueille P, Alves Saldanha S, Schaller F, et al. Real-life therapeutic concentration monitoring of long-acting cabotegravir and rilpivirine: preliminary results of an ongoing prospective observational study in Switzerland. Pharmaceutics. 2022;14(8):1588. doi: 10.3390/pharmaceutics14081588
   PubMed Web of Science ®Google Scholar
• Thoueille P, Saldanha SA, Schaller F, et al. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland. Lancet Reg Health Eur. 2023;36:100793. doi: 10.1016/j.lanepe.2023.100793
   PubMedGoogle Scholar
• van Welzen BJ, Van Lelyveld SFL, Ter Beest G, et al. Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis. Clin Infect Dis. 2024;[Epub ahead of print]. doi: 10.1093/cid/ciae016
   Google Scholar
• Sandaradura I, Alffenaar JW, Cotta MO, et al. Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: availability, performance and barriers to implementation. Br J Clin Pharmacol. 2022;88(2):669–679. doi: 10.1111/bcp.14995
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Fusi M, Colaneri M, et al. Therapeutic drug monitoring of dalbavancin in real life: a two-year experience. Antibiotics. 2023;13(1):20. doi: 10.3390/antibiotics13010020
   Google Scholar
• Schoretsanitis G, Meyer JM, Conca A, et al. Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2023;19(4):189–202. doi: 10.1080/17425255.2023.2220962
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Baumann P, Conca A, et al. Therapeutic drug monitoring of long-acting injectable antipsychotic drugs. Ther Drug Monit. 2021;43(1):79–102. doi: 10.1097/FTD.0000000000000830
   PubMed Web of Science ®Google Scholar
• Khalifa A, Stover J, Mahy M, et al. Demographic change and HIV epidemic projections to 2050 for adolescents and young people aged 15-24. Glob Health Action. 2019;12(1):1662685. doi: 10.1080/16549716.2019.1662685
   PubMed Web of Science ®Google Scholar
• García-Blanco D, Gravier-Hernández R, Rabeiro-Martínez CL, et al. Pharmacogenetic markers: a path toward individualized HIV Therapy. MEDICC Rev. 2019;21(2–3):59–68.
   PubMed Web of Science ®Google Scholar
• Mu Y, Kodidela S, Wang Y, et al. The dawn of precision medicine in HIV: state of the art of pharmacotherapy. Expert Opin Pharmacother. 2018;19(14):1581–1595. doi: 10.1080/14656566.2018.1515916
   PubMed Web of Science ®Google Scholar
• Cusato J, Allegra S, Nicolò A, et al. Precision medicine for HIV: where are we? Pharmacogenomics. 2018;19(2):145–165. doi: 10.2217/pgs-2017-0123
   PubMed Web of Science ®Google Scholar
• Kwara A, Lartey M, Sagoe KW, et al. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS. 2011;25(3):388–390. doi: 10.1097/QAD.0b013e3283427e05
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Astuti N, Montrasio C, et al. The case of multiple HIV virological failures in a compliant patient: do pharmacogenetics matter? J Antimicrob Chemother. 2024;79(2):471–473. doi: 10.1093/jac/dkad399
   PubMed Web of Science ®Google Scholar